摘要
目的观察孟鲁司特联合布地奈德治疗咳嗽变异性哮喘（CVA）的临床疗效及安全性。方法76例咳嗽变异性哮喘患儿随机分为两组，两组患儿均采用特布他林治疗，患儿症状缓解后停药，其中38例患儿加用孟鲁司特联合布地奈德治疗作为观察组，38例患儿加用布地奈德治疗作为对照组，均治疗3个月，观察比较两组患儿临床疗效，不良反应发生率，并随访两组患儿半年，观察比较其复发情况。结果观察组患儿治疗总有效率为97．37％，对照组患儿治疗总有效率为86．84％，观察组临床疗效明显优于对照组，两组差异有统计学意义（X^2=6．341，P〈0．05）。观察组2例（5．26％）出现药物不良反应，对照组5例（13．16％）出现药物不良反应，观察组药物不良反应发生率略低于对照组，但差异无统计学意义（P〉0．05）。观察组复发1例（2．63％），对照组复发2例（5．26％），两组差异无统计学意义（P〉0．05）。结论孟鲁司特联合布地奈德气雾剂治疗咳嗽变异性哮喘疗效显著，不良反应轻微，复发率低。
Objective To observe the clinical efficacy and safety of montelukast combined with budesonide in the treatment of children with cough variant asthma （ CVA ）. Methods 76 cases with CVA were randomly divided into two groups, two groups were treated with terbutaline, discontinuation of the drug after remission of symptoms. 38 cases in the observation group were treated with montelukast combined with budesonide ,38 cases in the control group were treated with budesonide. All the children were treated for 3 months. The clinical curative effect was compared be- tween the two groups. Follow-up for 6 months, the incidence of adverse reactions and recurrence were observed. Results The total effective rate of observation group was 97.37% ,which was higher than that in the control group 86.84%, the difference between the two groups was statistically significant （ P 〈 0.05 ）. The adverse reactions oc- curred in 2 cases （5.26%） of observation group,5 cases （ 13.16% ） in the control group. The incidence of adverse drug reaction rate was slightly lower than that of control group, but the difference was not significant （ P 〉 0.05 ）. The observation group had 1 case recurrence （2.63%）, the control group 2 cases of recurrence （5.26%）, the difference between the two groups was not statistically significant （ P 〉 0.05 ）. Conclusion Montelukast combined with budes- onide inhalation in treatment of children with CVA has significant efficacy, adverse reactions are mild, low recurrence rate.
出处
《中国基层医药》
CAS
2012年第24期3699-3700,共2页
Chinese Journal of Primary Medicine and Pharmacy
